August 1, 2025Open Access

Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy: A New Frontier in the Management of High-Risk Localized Prostate Cancer

View Full Paper

Ask AI

Bookmark

Authors

WKWhi‐An KwonMyongji Hospital JJJae Young JoungKorea Development Institute

Discussion

Member takes

Implication

Radioligand therapy shows promise in improving outcomes for localized prostate cancer, suggesting new challenges for patient selection and treatment metrics.

Key Points

Neoadjuvant 177Lu-PSMA-617 therapy aims to improve the management of high-risk localized prostate cancer.
Initial trials indicate safety and feasibility, but there is a lack of substantial pathologic complete responses.
Radioligand therapy may induce immunogenic cell death, potentially boosting responses to checkpoint inhibitors.
Validated surrogate endpoints and biomarkers are critical for assessing therapy success, with large-scale trials needed.

Cite This Study

Kwon et al. (2025) studied this question.

synapsesocial.com/papers/689a0c65e6551bb0af8cfa72 https://doi.org/10.20944/preprints202507.2543.v1

View Full Paper

Ask AI

Bookmark

Implication

Radioligand therapy shows promise in improving outcomes for localized prostate cancer, suggesting new challenges for patient selection and treatment metrics.

Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy: A New Frontier in the Management of High-Risk Localized Prostate Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy: A New Frontier in the Management of High-Risk Localized Prostate Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider